Microsecretory adenocarcinoma (MSA) is a salivary gland tumor that usually presents as a painless mass in the oral cavity. It was first described in case literature in 2019, with 24 definitive cases reported since its initial description. Of these cases, there is only one known to have arisen outside of the oral cavity; that case arose in the parotid gland. In this case, the authors present histomorphologic,
Category Archives: Clinical & Research Blog
Non-small-cell lung cancer (NSCLC) is a genetically heterogeneous disease. In approximately 2% of NSCLC cases, the primary oncogenic mutation is a chromosomal rearrangement involving ROS1 (c-ros oncogene 1), where one of many diverse gene partners fuses to the 3’ kinase domain of ROS1 and results in the constitutive activation of the ROS1 receptor tyrosine kinase.
Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, announces the acquisition of Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics.
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and a leading cause of death worldwide. Fortunately, the survival rate for NSCLC patients has been increasing, in large part due to advances in targeted molecular and immunotherapies. Somatic mutations and gene fusions that alter the receptor tyrosine kinase (RTK)/RAS/REF pathway are frequent
Paraneoplastic syndromes are rare disorders co-occurring with cancer that are not directly related to the local presence of tumor cells, but result from the generation of autoantibodies, cytokines, hormones, or peptides in response to the malignancy. These syndromes have complex manifestations that can affect multiple organ systems, including the neurological, dermatological, gastrointestinal, endocrine, hematologic, and cardiovascular systems; neurologic presentations are most common.
Treatment of non-small cell lung cancer (NSCLC), which represents 80-85% of lung cancer cases, has drastically changed over the past two decades with the development of molecularly targeted therapies, including tyrosine kinase inhibitors.
Modern classification of mammary tumors depends on both histomorphology and molecular analyses. The most common histological type of breast cancer, accounting for approximately 80% of breast carcinoma cases, is invasive ductal carcinoma, classified as invasive breast carcinoma of no special type (IBC-NST) by the fifth edition of the WHO Classification of Tumors of the Breast.
The aggressive basal-like breast cancer (BLBC) subtype, which strongly correlates with triple-negative (ER- PR- HER2-) breast cancers, comprises 15-20% of all breast cancer cases and has a poor prognosis, largely resulting from a lack of a molecularly-targeted treatment regimen. Loss of control of signaling pathways frequently triggers tumorigenesis, and molecules involved in these signaling pathways are frequent molecular treatment targets.
Squamous cell carcinoma (SCC), which develops in the top layer of the epithelium, and adenocarcinoma (AC), which develops in glandular epithelium cells, are two of the primary histological subtypes of carcinoma.
Multiple myeloma (MM) is a genetically heterogeneous disease, and this genetic heterogeneity can contribute to varied clinical responses and survival outcomes among patients. One of the most common cytogenetic abnormalities, occurring in around 40% of newly diagnosed MM cases and up to 70% of relapsed/refractory MM cases,